药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Clotiazepam
Ensituximab
Estradiol valerate may increase the thrombogenic activities of Ensituximab.
Clotiazepam
Tanezumab
Estradiol valerate may increase the thrombogenic activities of Tanezumab.
Clotiazepam
Labetuzumab govitecan
Estradiol valerate may increase the thrombogenic activities of Labetuzumab govitecan.
Clotiazepam
Vanucizumab
Estradiol valerate may increase the thrombogenic activities of Vanucizumab.
Clotiazepam
GS-5745
Estradiol valerate may increase the thrombogenic activities of GS-5745.
Clotiazepam
Luspatercept
Estradiol valerate may increase the thrombogenic activities of Luspatercept.
Clotiazepam
Aducanumab
Estradiol valerate may increase the thrombogenic activities of Aducanumab.
Clotiazepam
Ascrinvacumab
Estradiol valerate may increase the thrombogenic activities of Ascrinvacumab.
Clotiazepam
Cixutumumab
Estradiol valerate may increase the thrombogenic activities of Cixutumumab.
Clotiazepam
Inclacumab
Estradiol valerate may increase the thrombogenic activities of Inclacumab.
Clotiazepam
Etaracizumab
Estradiol valerate may increase the thrombogenic activities of Etaracizumab.
Clotiazepam
Ganitumab
Estradiol valerate may increase the thrombogenic activities of Ganitumab.
Clotiazepam
Zalutumumab
Estradiol valerate may increase the thrombogenic activities of Zalutumumab.
Clotiazepam
Etrolizumab
Estradiol valerate may increase the thrombogenic activities of Etrolizumab.
Clotiazepam
Tralokinumab
Estradiol valerate may increase the thrombogenic activities of Tralokinumab.
Clotiazepam
Dupilumab
Estradiol valerate may increase the thrombogenic activities of Dupilumab.
Clotiazepam
Fasinumab
Estradiol valerate may increase the thrombogenic activities of Fasinumab.
Clotiazepam
Simtuzumab
Estradiol valerate may increase the thrombogenic activities of Simtuzumab.
Clotiazepam
Duligotuzumab
Estradiol valerate may increase the thrombogenic activities of Duligotuzumab.
Clotiazepam
Gevokizumab
Estradiol valerate may increase the thrombogenic activities of Gevokizumab.